

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: BRÖGMANN, Bianca et al. Confirmation No.: 1884
Serial No.: 10/510,674 Art Unit: 1617
Filed: May 23, 2005 Examiner: CAPPs, Kevin J.
For: PHARMACEUTICAL
PREPARATION
CONTAINING OXYCODONE
AND NALOXONE
Attorney Docket No.: Y2428-00162

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandra, VA 22313-1450

Sir:


In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to References **A09-A12**, and **C08** which are listed on the accompanying Forms PTO/SB/8A, Form PTO/SB/8B both entitled "Information Disclosure Statement By Applicant" both of which are in compliance with 37 C.F.R. § 1.98. Copies of References **A09-A12** are not submitted herewith pursuant to 37 C.F.R. §§ 1.98(a)(2)(i), since these references are U.S. patent documents. A copy of Reference **C08** is submitted herewith. Applicants will furnish copies of any and all references to the Examiner upon request.

In accordance with 37 C.R.F. § 1.97(h), identification of the listed references is not to be construed as an admission that such reference is available as "prior art" against the subject application, as defined by 37 C.R.F. § 1.56(b). Applicants request that the Examiner review the references identified on the attached Forms PTO/SB/8A and PTO/SB/8B, and that they be made of record in the file history of this application.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application. A fee in the amount of \$180.00, as set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is believed to be due. The Commissioner is authorized to charge such fee to Duane Morris LLP Deposit Account No. 04-1679.

Date: March 19, 2009

Respectfully submitted,


Graham C. Alig
Duane Morris LLP
1540 Broadway
New York, NY 10036
Tel. (212) 692-1000
Fax. (212) 692-1086

55,768
(Reg. No.)

Enclosures